Alteration of Epigenetic Modifiers in Pancreatic Cancer and Its Clinical Implication
1
National Institute of Cancer Research, National Health Research Institutes, Tainan 704, Taiwan
2
Division of Hematology/Oncology, Department of Internal Medicine, National Cheng Kung University Hospital, Tainan 704, Taiwan
3
Institute of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan
4
Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan
5
Center for Cancer Research, Kaohsiung Medical University, Kaohsiung 807, Taiwan
6
Department of Medical Research, Kaohsiung Medical University Hospital, Kaohsiung 807, Taiwan
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2019, 8(6), 903; https://doi.org/10.3390/jcm8060903
Received: 30 May 2019
/
Revised: 15 June 2019
/
Accepted: 20 June 2019
/
Published: 24 June 2019
(This article belongs to the Special Issue Current Standards and New Innovative Approaches for Treatment of Pancreatic Cancer)
The incidence of pancreatic cancer has considerably increased in the past decade. Pancreatic cancer has the worst prognosis among the cancers of the digestive tract because the pancreas is located in the posterior abdominal cavity, and most patients do not show clinical symptoms for early detection. Approximately 55% of all patients are diagnosed with pancreatic cancer only after the tumors metastasize. Therefore, identifying useful biomarkers for early diagnosis and screening high-risk groups are important to improve pancreatic cancer therapy. Recent emerging evidence has suggested that genetic and epigenetic alterations play a crucial role in the molecular aspects of pancreatic tumorigenesis. Here, we summarize recent progress in our understanding of the epigenetic alterations in pancreatic cancer and propose potential synthetic lethal strategies to target these genetic defects to treat this deadly disease.
View Full-Text
Keywords:
pancreatic cancer; epigenetic regulation; SWItch/Sucrose Non-Fermentable (SWI/SNF) complex; histone methylation; synthetic lethality
▼
Show Figures
Figure 1
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
MDPI and ACS Style
Hung, Y.-H.; Hsu, M.-C.; Chen, L.-T.; Hung, W.-C.; Pan, M.-R. Alteration of Epigenetic Modifiers in Pancreatic Cancer and Its Clinical Implication. J. Clin. Med. 2019, 8, 903. https://doi.org/10.3390/jcm8060903
AMA Style
Hung Y-H, Hsu M-C, Chen L-T, Hung W-C, Pan M-R. Alteration of Epigenetic Modifiers in Pancreatic Cancer and Its Clinical Implication. Journal of Clinical Medicine. 2019; 8(6):903. https://doi.org/10.3390/jcm8060903
Chicago/Turabian StyleHung, Yu-Hsuan, Ming-Chuan Hsu, Li-Tzong Chen, Wen-Chun Hung, and Mei-Ren Pan. 2019. "Alteration of Epigenetic Modifiers in Pancreatic Cancer and Its Clinical Implication" Journal of Clinical Medicine 8, no. 6: 903. https://doi.org/10.3390/jcm8060903
Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.
